Abstract
The effects of dose reduction or spacing of all types of biologics in rheumatoid arthritis has not been consistently assessed in systematic reviews. We aimed to assess the effects of biologics reduction compared with dose maintenance in patients with rheumatoid arthritis in low disease activity or remission. We performed a systematic review with meta-analysis according to a previously registered protocol (PROSPERO registration: CRD42017069080); and searched MEDLINE, Embase, Scopus, Cochrane Library and trial registers up to July, 2020. Two researchers selected, extracted and assessed the risk of bias of controlled trials that randomized patients to reduction/spacing or dose maintenance of biologics. Low disease activity, disability and other clinically important outcomes were summarized in random effect meta-analyses. We rated the certainty of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation approach. We included ten studies (n = 1331 patients), which assessed reduction or spacing of abatacept, adalimumab, certolizumab pegol, etanercept, or tocilizumab. Risk of bias was high in over half of trials, mainly due to lack of blinding. No statistically significant difference was found in low disease activity (RR = 0.90; 95% CI 0.78–1.04; I2 = 60%, very low certainty), and other outcomes. Subgroup analysis of blinded studies led to homogeneous results, which remained heterogeneous in open-label studies. Reduction or spacing biologics did not affect disease activity and other important outcome. Changes in the doses regimen should consider patient preferences, considering the low certainty of evidence.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00296-020-04651-z/MediaObjects/296_2020_4651_Fig1_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00296-020-04651-z/MediaObjects/296_2020_4651_Fig2_HTML.png)
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00296-020-04651-z/MediaObjects/296_2020_4651_Fig3_HTML.png)
Similar content being viewed by others
Data transparency
The datasets generated and/or analysed in the current study are available at https://figshare.com/s/87b483b95387fdfe33a2.
Abbreviations
- bDMARD:
-
Biologic disease modifying antirheumatic drugs
- CI:
-
Confidence interval
- DAS28:
-
Disease activity score of 28 joints
- GRADE:
-
Grading of Recommendations Assessment, Development, and Evaluation
- HAQ-DI:
-
Health assessment questionnaire-disability index
- TNFi:
-
Tumour necrosis factor inhibitors
- PGA:
-
Patient global assessment
- RR:
-
Relative risk
- SMD:
-
Standardized mean difference
References
Costello R, David T, Jani M (2019) Impact of adverse events associated with medications in the treatment and prevention of rheumatoid arthritis. Clin Ther 41(7):1376–1396. https://doi.org/10.1016/j.clinthera.2019.04.030
Heidari P, Cross W, Weller C, Nazarinia M, Crawford K (2019) Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: a cross-sectional study. Int J Rheum Dis 22(4):555–566. https://doi.org/10.1111/1756-185x.13549
Galvao TF, Zimmermann IR, da Mota LMH, Silva MT, Pereira MG (2016) Withdrawal of biologic agents in rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 35(7):1659–1668
Hewlett S, Haig-Ferguson A, Rose-Parfitt E, Halls S, Freke S, Creamer P (2019) Dose reduction of biologic therapy in inflammatory arthritis: a qualitative study of patients' perceptions and needs. Musculoskeletal Care 17(1):63–71. https://doi.org/10.1002/msc.1367
Jiang M, Ren F, Zheng Y, Yan R, Huang W, **a N, Luo L, Zhou J, Tang L (2017) Efficacy and safety of down-titration versus continuation strategies of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis with low disease activity or in remission: a systematic review and meta-analysis. Clin Exp Rheumatol 35(1):152–160
Kuijper TM, Lamers-Karnebeek FB, Jacobs JW, Hazes JM, Luime JJ (2015) Flare rate in patients with rheumatoid arthritis in low disease activity or remission when tapering or stop** synthetic or biologic DMARD: a systematic review. J Rheumatol 42:2012–2022
Verhoef LM, van den Bemt BJ, van der Maas A, Vriezekolk JE, Hulscher ME, van den Hoogen FH, Jacobs WC, van Herwaarden N, den Broeder AA (2019) Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity. Cochrane Database Syst Rev 5:Cd010455. https://doi.org/10.1002/14651858.CD010455.pub3
Montori VM, Guyatt GH (2001) Intention-to-treat principle. CMAJ 165(10):1339–1341
Higgins JPT, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savović J, Schulz KF, Weeks L, Sterne JAC (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. https://doi.org/10.1136/bmj.d5928
Borenstein M, Hedges LV, Higgins JP, Rothstein HR (2010) A basic introduction to fixed-effect and random-effects models for meta-analysis. Res Synth Methods 1(2):97–111. https://doi.org/10.1002/jrsm.12
IntHout J, Ioannidis JP, Rovers MM, Goeman JJ (2016) Plea for routinely presenting prediction intervals in meta-analysis. BMJ Open 6(7):e010247. https://doi.org/10.1136/bmjopen-2015-010247
Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558. https://doi.org/10.1002/sim.1186
Harbord RM, Higgins JPT (2008) Meta-regression in Stata. Stata J 8(4):493–519
** Z-C, Zhou X-H, He J (2015) Statistical methods for dealing with publication bias in meta-analysis. Stat Med 34(2):343–360. https://doi.org/10.1002/sim.6342
Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, Carr A, Hughes R (2005) Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care 3(3):131–142. https://doi.org/10.1002/msc.3
Sanderson T, Morris M, Calnan M, Richards P, Hewlett S (2010) Patient perspective of measuring treatment efficacy: the rheumatoid arthritis patient priorities for pharmacologic interventions outcomes. Arthritis Care Res 62(5):647–656. https://doi.org/10.1002/acr.20151
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924–926. https://doi.org/10.1136/bmj.39489.470347.AD
Westhovens R, Robles M, **menes AC, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Murthy B (2015) Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis 74(3):564–568. https://doi.org/10.1136/annrheumdis-2014-206149
Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park M-C, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B (2013) Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial. Lancet 381(9870):918–929. https://doi.org/10.1016/S0140-6736(12)61811-X
Fautrel B, Pham T, Alfaiate T, Gandjbakhch F, Foltz V, Morel J, Dernis E, Gaudin P, Brocq O, Solau-Gervais E, Berthelot JM, Balblanc JC, Mariette X, Tubach F (2016) Step-down strategy of spacing TNF-blocker injections for established rheumatoid arthritis in remission: results of the multicentre non-inferiority randomised open-label controlled trial (STRASS: Spacing of TNF-blocker injections in Rheumatoid Arthritis Study). Ann Rheum Dis 75(1):59–67. https://doi.org/10.1136/annrheumdis-2014-206696
van Vollenhoven RF, Østergaard M, Leirisalo-Repo M, Uhlig T, Jansson M, Larsson E, Brock F, Franck-Larsson K (2016) Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis. Ann Rheum Dis 75(1):52–58. https://doi.org/10.1136/annrheumdis-2014-205726
Okano T, Inui K, Tada M, Sugioka Y, Mamoto K, Koike T, Nakamura H (2015) FRI0137 medication interval of adalimumab for rheumatoid arthritis patients might be extended after the achievement of low disease activity-kabuki study. BMJ Publishing Group Ltd
Ibrahim F, Lorente-Cánovas B, Doré CJ, Bosworth A, Ma MH, Galloway JB, Cope AP, Pande I, Walker D, Scott DL (2017) Optimizing treatment with tumour necrosis factor inhibitors in rheumatoid arthritis—a proof of principle and exploratory trial: is dose tapering practical in good responders? Rheumatology 56:2004–2014
van Herwaarden N, van der Maas A, Minten MJ, van den Hoogen FH, Kievit W, van Vollenhoven RF, Bijlsma JW, van den Bemt BJ, den Broeder AA (2015) Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial. BMJ 350:h1389. https://doi.org/10.1136/bmj.h1389
l’Ami MJ, Krieckaert CL, Nurmohamed MT, van Vollenhoven RF, Rispens T, Boers M, Wolbink GJ (2017) Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis. https://doi.org/10.1136/annrheumdis-2017-211781
Weinblatt ME, Bingham CO, Burmester GR, Bykerk VP, Furst DE, Mariette X, van der Heijde D, van Vollenhoven R, Van Lunen B, Ecoffet C (2017) A phase 3 study evaluating continuation, tapering, and withdrawal of certolizumab pegol after 1 year of therapy in early rheumatoid arthritis patients. Arthritis Rheumato 69:1937–1948
El Miedany Y, El Gaafary M, Youssef S, Ahmed I, Bahlas S, Hegazi M, Nasr A (2016) Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stop** treatment for rheumatoid arthritis patients achieving clinical and radiological remission. Clin Rheumatol 35(12):2915–2923
Sigaux J, Bailly F, Hajage D, Mariette X, Morel J, Gandjbakhch F, Foltz V, Gossec L, Tubach F, Fautrel B (2017) Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial. RMD Open 3(2):e000474
Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L (2017) Industry sponsorship and research outcome. Cochrane Database Syst Rev 2:MR000033. https://doi.org/10.1002/14651858.MR000033.pub3
Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64(4):401–406. https://doi.org/10.1016/j.jclinepi.2010.07.015
den Broeder AA, van der Maas A, van den Bemt BJ (2010) Dose de-escalation strategies and role of therapeutic drug monitoring of biologics in RA. Rheumatology 49(10):1801–1803. https://doi.org/10.1093/rheumatology/keq060
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, Gluud C, Martin RM, Wood AJG, Sterne JAC (2008) Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336(7644):601–605. https://doi.org/10.1136/bmj.39465.451748.AD%JBMJ
Fautrel B, den Broeder AA (2015) De-intensifying treatment in established rheumatoid arthritis (RA): why, how, when and in whom can DMARDs be tapered? Best Pract Res Clin Rheumatol 29(4):550–565. https://doi.org/10.1016/j.berh.2015.09.006
Higgins J, Green S (2011) Cochrane handbook for systematic reviews of interventions. https://handbook.cochrane.org/
Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 291(20):2457–2465
Tierney JF, Stewart LA (2004) Investigating patient exclusion bias in meta-analysis. Int J Epidemiol 34(1):79–87
Pildal J, Hrobjartsson A, Jørgensen K, Hilden J, Altman D, Gøtzsche P (2007) Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol 36(4):847–857
Als-Nielsen B, Gluud L, Gluud C (2004) Methodological quality and treatment effects in randomized trials: a review of six empirical studies. 12th Cochrane Colloqium. Ottawa (Canada)
Barragán-Martínez C, Amaya-Amaya J, Pineda-Tamayo R, Mantilla RD, Castellanos-de la Hoz J, Bernal-Macías S, Rojas-Villarraga A, Anaya JM (2012) Gender differences in Latin-American patients with rheumatoid arthritis. Gend Med 9(6):490–510.e495. https://doi.org/10.1016/j.genm.2012.10.005
Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, Churchman SM, Quinn M, Wakefield R, Conaghan PG, Ponchel F, Emery P (2010) Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 69(9):1636–1642. https://doi.org/10.1136/ard.2009.117341
Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, Nojima T, Miyasaka N, Koike T, investigators Rs (2010) Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 69(7):1286–1291. https://doi.org/10.1136/ard.2009.121491
Chen DY, Chen YM, Hsieh TY, Hung WT, Hsieh CW, Chen HH, Tang KT, Lan JL (2016) Drug trough levels predict therapeutic responses to dose reduction of adalimumab for rheumatoid arthritis patients during 24 weeks of follow-up. Rheumatology 55(1):143–148. https://doi.org/10.1093/rheumatology/kev298
Tweehuysen L, van den Ende CH, Beeren FM, Been EM, van den Hoogen FH, den Broeder AA (2017) Little evidence for usefulness of biomarkers for predicting successful dose reduction or discontinuation of a biologic agent in rheumatoid arthritis: a systematic review. Arthritis Rheumatol 69(2):301–308. https://doi.org/10.1002/art.39946
Singh JA, Wells GA, Christensen R, Tanjong Ghogomu E, Maxwell L, Macdonald JK, Filippini G, Skoetz N, Francis D, Lopes LC, Guyatt GH, Schmitt J, La Mantia L, Weberschock T, Roos JF, Siebert H, Hershan S, Lunn MP, Tugwell P, Buchbinder R (2011) Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2:Cd008794. https://doi.org/10.1002/14651858.CD008794.pub2
Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology 52(1):53–61. https://doi.org/10.1093/rheumatology/kes305
Tarp S, Eric Furst D, Boers M, Luta G, Bliddal H, Tarp U, Heller Asmussen K, Brock B, Dossing A, Schjodt Jorgensen T, Thirstrup S, Christensen R (2016) Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology. https://doi.org/10.1093/rheumatology/kew442
Acknowledgements
The authors thank Jessica Quintão Pereira for the contribution data extraction and risk of bias assessment, the authors of included manuscripts Rene Westhovens, Alfons den Broeder, Tatsuya Koike, and Yasser el Miedany for providing extra data from upon our requested, and Espaço da Escrita, Pró-Reitoria de Pesquisa, Unicamp for the language revision service.
Funding
Leticia Breda e Vasconcelos received an undergraduate scholarship from the program of scientific initiation fellowships of University of Campinas, funded by the National Council of Scientific and Technological Development (CNPq).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Vasconcelos, L.B., Silva, M.T. & Galvao, T.F. Reduction of biologics in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatol Int 40, 1949–1959 (2020). https://doi.org/10.1007/s00296-020-04651-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00296-020-04651-z